TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
批准号:
3175432
负责人:
Tsann Ming Chu
金额:
$21.41万
依托单位国家:
美国
项目类别:
财政年份:
1984
资助国家:
美国
项目状态:
已结题
起止时间:
1984-08-15 至 1991-01-31
关键词:
antibody specificity bone marrow bone marrow neoplasms breast neoplasms cancer registry /resource carcinoma combination cancer therapy doxorubicin histopathology human therapy evaluation human tissue metal complex metastasis mixed tissue /cell culture molecular oncology monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer remission /regression neoplasm /cancer transplantation ovary neoplasms radioimmunoassay radiotracer tumor antigens xenotransplantation
中文摘要
单抗F36/22(1GG/3,识别糖蛋白
7001000K的MR)已被免疫组织化学显示为
对所有人类常见的上皮性肿瘤,卵巢癌,
而正常卵巢不表达可检测到的免疫染色。
人卵巢脱落的肿瘤细胞通常正在扩散
贯穿整个腹膜腔,代表着一种理想的
在密闭隔间中进行治疗操作的靶标。
新近建立的人卵巢癌异种移植模型
雌性裸鼠NIH:OVCAR-3表达抗原
由单抗F36/22识别,类似于
通过产生腹水和腹内而引起的人类疾病
癌症。用单抗F36/22作为探针
和NIH:OVCAR-3作为体内模型,我们将开发和
评价有效的放射免疫治疗的靶向和
消除腹膜卵巢肿瘤种植。阿霉素,一种
卵巢癌常用的细胞毒剂,将
与单抗F36/22偶联用于腔内治疗
卵巢肿瘤的免疫化疗。两者的有效性
生物反应调节剂将加强治疗。
建议的使用独一无二的单抗的方法
抗体在卵巢癌靶向治疗中的应用
很少或根本不与他人沟通的空腔隔间
身体隔间将产生明确和有用的临床前
信息。
英文摘要
Monoclonal antibody F36/22 (1gG/3, recognizes a glycoprotein
with Mr of 7001000K) has been shown immunohistochemically to
be reactive with all human common epithelial, ovarian cancers,
while normal ovary expresses no detectable level of immunostain.
Human exfoliated ovarian tumor cells are usually disseminating
throughout the entire peritoneal cavity, and represent an ideal
target for therapeutic manipulation in a confined compartment.
A recently available human ovarian carcinoma xenograft in
female athymic mice, NIH:OVCAR-3, expresses antigen
recognized by monoclonal antibody F36/22 and resembles the
human disease by producing ascites and intra-abdominal
carcinomatosis. Using monoclonal antibody F36/22 as the probe
and NIH:OVCAR-3 as the in vivo model, we will develop and
evaluate effective radioimmunotherapy for the targeting and
elimination of peritoneal ovarian tumor seedings. Adriamycin, a
commonly used cytotoxic agent in ovarian cancer, will be
conjugated to monoclonal antibody F36/22 for intracavity
immunochemotherapy of ovarian tumor. Effectiveness of both
therapies will be potentiated by biological response modifiers.
The proposed approaches to the use of a unique monoclonal
antibody in targeting and therapy of ovarian cancer in a confined
cavity compartment with little or no communication with other
body compartments will generate defined and useful preclinical
information.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
-
批准号:3175435
-
项目类别:
-
资助金额:$11.26万
-
财政年份:1984
-
负责人:Tsann Ming Chu
-
依托单位:
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
-
批准号:3175437
-
项目类别:
-
资助金额:$10.08万
-
财政年份:1984
-
负责人:Tsann Ming Chu
-
依托单位:
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
-
批准号:3175434
-
项目类别:
-
资助金额:$10.98万
-
财政年份:1984
-
负责人:Tsann Ming Chu
-
依托单位:
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
-
批准号:3175436
-
项目类别:
-
资助金额:$14.17万
-
财政年份:1984
-
负责人:Tsann Ming Chu
-
依托单位:
BREAST CARCINOMA ANTIGENS F36/22 AND M7/105
-
批准号:3172050
-
项目类别:
-
资助金额:$9.79万
-
财政年份:1983
-
负责人:Tsann Ming Chu
-
依托单位:
ANTIGEN-ANTIBODY COMPLEXES IN BREAST CANCER
-
批准号:3166984
-
项目类别:
-
资助金额:$9.54万
-
财政年份:1979
-
负责人:Tsann Ming Chu
-
依托单位:
BIOLOGICAL MARKERS IN TREATMENT OF PROSTATE CANCER
-
批准号:3556295
-
项目类别:
-
资助金额:$6.54万
-
财政年份:1979
-
负责人:Tsann Ming Chu
-
依托单位:
ANTIGEN MARKERS IN DIAGNOSIS OF PROSTATE CANCER
-
批准号:3164177
-
项目类别:
-
资助金额:$10.01万
-
财政年份:1976
-
负责人:Tsann Ming Chu
-
依托单位:
海外基金